CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Rifamycin

利福霉素 杂质对照品Rifamycin Impurities

EP16 个杂质条目16 impurity entries

本页汇总 利福霉素 的 16 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 16 impurity reference standards of Rifamycin with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 利福霉素(Rifamycin)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsSimultaneous Determination of Rifamycin Antibiotics and Their Active Metabolites in Human Plasma Using UHPLC-MS/MS to Evaluate Their Impact on Target Peak Concentrations: A Short Communication
    Therapeutic drug monitoring · 2023 · Wu LJ et al.  ·  PMID 37074816  ·  DOI
  2. 分析方法Analytical MethodsDetermination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC/MS/MS
    Journal of pharmaceutical and biomedical analysis · 2015 · Winchester LC et al.  ·  PMID 25481085  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisRifamycin Biosynthetic Congeners: Isolation and Total Synthesis of Rifsaliniketal and Total Synthesis of Salinisporamycin and Saliniketals A and B
    Journal of the American Chemical Society · 2016 · Feng Y et al.  ·  PMID 27232659  ·  DOI
  • 合成方法SynthesisCrotylboron-based synthesis of the polypropionate units of chaxamycins A/D, salinisporamycin, and rifamycin S
    The Journal of organic chemistry · 2013 · Chen M, Roush WR  ·  PMID 22703288  ·  DOI
  • 合成方法SynthesisExpeditious asymmetric synthesis of a stereoheptad corresponding to the C(19)-C(27)-ansa chain of rifamycins: formal total synthesis of Rifamycin S
    Chemistry (Weinheim an der Bergstrasse, Germany) · 2005 · Turks M et al.  ·  PMID 15551311  ·  DOI

利福霉素 —— 原料药与杂质对照品Rifamycin — drug substance & impurities

共 16 个条目(含原料药本体)16 items incl. the drug substance
Rifamycin Impurity 1 (Rifamycin Sodium EP Impurity A) (Rifamycin B) structure
EPA
利福霉素杂质1 (利福霉素钠EP杂质A) (利福霉素B)Rifamycin Impurity 1 (Rifamycin Sodium EP Impurity A) (Rifamycin B)
Rifamycin Impurity 1 (Rifamycin Sodium EP Impurity A) (Rifamycin B)
CAS No.13929-35-6
Chemical FormulaC39H49NO14
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 2 Sodium Salt(Rifamycin EP Impurity B Sodium Salt)(Rifamycin S Sodium Salt) structure
EPB
利福霉素杂质2 钠盐(利福霉素EP杂质B 钠盐)(利福霉素S 钠盐)Rifamycin Impurity 2 Sodium Salt(Rifamycin EP Impurity B Sodium Salt)(Rifamycin S Sodium Salt)
Rifamycin Impurity 2 Sodium Salt(Rifamycin EP Impurity B Sodium Salt)(Rifamycin S Sodium Salt)
CAS No.133956-65-7
Chemical FormulaC37H44NO12-·Na+
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 2 (Rifamycin EP Impurity B) (Rifamycin S) structure
EPB
利福霉素杂质2 (利福霉素EP杂质B) (利福霉素S)Rifamycin Impurity 2 (Rifamycin EP Impurity B) (Rifamycin S)
Rifamycin Impurity 2 (Rifamycin EP Impurity B) (Rifamycin S)
CAS No.13553-79-2
Chemical FormulaC37H45NO12
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 3 (Rifamycin Sodium EP Impurity C) (Rifamycin O) structure
EPC
利福霉素杂质3 (利福霉素钠EP杂质C) (利福霉素O)Rifamycin Impurity 3 (Rifamycin Sodium EP Impurity C) (Rifamycin O)
Rifamycin Impurity 3 (Rifamycin Sodium EP Impurity C) (Rifamycin O)
CAS No.14487-05-9
Chemical FormulaC39H47NO14
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 4 (25-Desacetyl Rifamycin S) structure
4
利福霉素杂质4 (25-去乙酰基利福霉素S)Rifamycin Impurity 4 (25-Desacetyl Rifamycin S)
Rifamycin Impurity 4 (25-Desacetyl Rifamycin S)
CAS No.17555-51-0
Chemical FormulaC35H43NO11
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 5 structure
5
利福霉素杂质5Rifamycin Impurity 5
Rifamycin Impurity 5
CAS No.56908-32-8
Chemical FormulaC38H49NO12S
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 6 structure
6
利福霉素杂质6Rifamycin Impurity 6
Rifamycin Impurity 6
CAS No.57375-25-4
Chemical FormulaC37H44BrNO12
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 7 structure
7
利福霉素杂质7Rifamycin Impurity 7
Rifamycin Impurity 7
CAS No.59886-91-8
Chemical FormulaC37H44N4O12
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 8 (Rifamycin Y) structure
8
利福霉素杂质8 (利福霉素Y)Rifamycin Impurity 8 (Rifamycin Y)
Rifamycin Impurity 8 (Rifamycin Y)
CAS No.15271-73-5
Chemical FormulaC39H47NO15
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 9 (16-Hydroxymethyl Rifamycin S) structure
9
利福霉素杂质9 (16-羟甲基利福霉素S)Rifamycin Impurity 9 (16-Hydroxymethyl Rifamycin S)
Rifamycin Impurity 9 (16-Hydroxymethyl Rifamycin S)
CAS No.59264-04-9
Chemical FormulaC37H45NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 12 (25-Desacetyl Rifamycin) structure
12
利福霉素杂质12 (25-去乙酰基利福霉素)Rifamycin Impurity 12 (25-Desacetyl Rifamycin)
Rifamycin Impurity 12 (25-Desacetyl Rifamycin)
CAS No.17750-90-2
Chemical FormulaC35H45NO11
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 16 structure
16
利福霉素杂质16Rifamycin Impurity 16
Rifamycin Impurity 16
CAS No.31718-67-9
Chemical FormulaC36H45NO12
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 17 (Rifamycin L) structure
17
利福霉素杂质17 (利福霉素 L)Rifamycin Impurity 17 (Rifamycin L)
Rifamycin Impurity 17 (Rifamycin L)
CAS No.26117-02-2
Chemical FormulaC39H49NO14
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 18 (27-Desmethyl Rifamycin S) structure
18
利福霉素杂质18 (27-去甲基利福霉素S)Rifamycin Impurity 18 (27-Desmethyl Rifamycin S)
Rifamycin Impurity 18 (27-Desmethyl Rifamycin S)
CAS No.32259-67-9
Chemical FormulaC36H43NO12
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 19 (Rifamycin G) structure
19
利福霉素杂质19 (利福霉素G)Rifamycin Impurity 19 (Rifamycin G)
Rifamycin Impurity 19 (Rifamycin G)
CAS No.59996-09-7
Chemical FormulaC36H47NO12
Purity>95%询价On request
10mg25mg50mg100mg
Rifamycin Impurity 20 (3-Hydroxyrifamycin S) structure
20
利福霉素杂质20 (3-羟基利福霉素 S)Rifamycin Impurity 20 (3-Hydroxyrifamycin S)
Rifamycin Impurity 20 (3-Hydroxyrifamycin S)
CAS No.75922-14-4
Chemical FormulaC37H45NO13
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

利福霉素 —— 研究文献与合成路线Rifamycin — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 利福霉素 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Rifamycin. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Characterization of the Rifamycin-Degrading Monooxygenase From Rifamycin Producers Implicating Its Involvement in Saliniketal Biosynthesis
    Zheng XF, Liu XQ, Peng SY, et al. · Frontiers in microbiology · 2020 · 被引 7cited 7
  2. Rifamycin O as a novel CRBN ligand for targeted degradation of IKZF1/3 proteins in hematopoietic malignancies
    Liao L, Wang Q, Gao Z, et al. · Acta pharmaceutica Sinica. B · 2026
  3. A novel degradation of rifamycin: isolation of the new ansa chain derivative from rifampicin
    Kinoshita M, Tatsuta K, Nakata M · The Journal of antibiotics · 1978
  4. High-performance liquid chromatographic assay for two rifamycin-derived hypocholesterolemic agents in liver and biological fluids
    Moore DJ, Perrino PJ, Klerer CP, et al. · Journal of chromatography · 1993 · 被引 3cited 3

合成与制备工艺专利Synthesis & process patents

  1. PHARMACEUTICAL PREPARATION FOR DELIVERING RIFAMYCIN DERIVATIVE TO DAMAGED TISSUE
    HAYASHI SHINJI, ICHIMURA MASANORI, KAWAZU MASASHI, JITSUYASU TAKAOKI · 公开号 JP2009137922JP2009137922 · 2009
  2. Method for preparing 3-amido-4-imino rifamycin S
    YANG JUN, PENG LI, XIAOQI YU, YONG WANG · 公开号 CN101200472CN101200472 · 2008
  3. Process for production of rifamycin b by an improved bacterial strain
    EL-TAYEB OSSAMA MOHAMMED, AISHA ABD EL-AZIZ SALAM · 公开号 EG23519EG23519 · 2006
  4. METHOD FOR PREPARING 3-AMINO-DERIVATIVES OF RIFAMYCIN S
    OVCHINNIKOV D V, POLUKEEV V A · 公开号 RU2245336RU2245336 · 2005
  5. METHOD FOR PREPARING 3-AZIDO-DERIVATIVES OF RIFAMYCIN S
    OVCHINNIKOV D V, POLUKEEV V A · 公开号 RU2245337RU2245337 · 2005

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

利福霉素 杂质谱研究要点Rifamycin — impurity profiling notes

下面这些是拿到 利福霉素 的 16 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 16 impurity entries for Rifamycin, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances